#Lorlatinib Achieved Rapid #CNS Response in an 81-Year-Old #NSCLC Patient With Performance Status Deterioration
onlinelibrary.wiley.com/doi/10.1002/...

Lorbrexen 100 mg (Lorlatinib) | Online International Pharmacy Lorbrexen 100 mg (Lorlatinib) is a targeted therapy for ALK-positive non-small cell lung cancer, inhibiting tumor growth and spread.

Lorbrexen 100 mg (Lorlatinib) is an oral targeted therapy used to treat ALK-positive or ROS1-positive non-small cell lung cancer, effectively these kinases to slow tumor growth and prevent cancer progression.
#Lorbrexen100mg #Lorlatinib #OnlineMedicine #Oncology #Health
jnspharma.com/product/lorb...

¿Qué sabes sobre el tratamiento #Lorlatinib?

No te pierdas todo sobre el tema en nuestro evento de Terapias Dirigidas de Cáncer de Pulmón 2025 con el Dr. Daniel Rosas: give.cancergrace.org/event/foro-d...

❗Sets a new benchmark for targeted therapies in oncology!

#Onco404 #Cancer #Oncology #LungCancer #ALKpositive #Lorlatinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #JCO

🎉 This represents the longest PFS ever reported with any single-agent targeted therapy in advanced NSCLC and across metastatic solid tumors ✨

#Onco404 #Cancer #Oncology #LungCancer #ALKpositive #Lorlatinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #JCO

📍Progression-Free Survival 📊
✅ Median PFS: NR with lorlatinib 🆚 9.1 months with crizotinib.
✅ 5-Year PFS: 60% (lorlatinib) vs. 8% (crizotinib).

#Onco404 #Cancer #Oncology #LungCancer #ALKpositive #Lorlatinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #JCO

I'm not a basic science person at all, but listening to #GrandRounds on tyrosine-kinase inhibitors in Stage 4 non-small cell #lungcancer and damn...70% alive at 6 years with #lorlatinib? Impressive. Thanks to those of you in #cancer research. My job: make it affordable to people not named Elon Musk

Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations. We present overall su...

Final survival from phase II study of #lorlatinib in #ALK #NSCLC. In treatment naive (n=30), 5y OS 76%

www.jto.org/article/S155...

Trial results for new lung cancer drug are ‘off the charts’, say doctors More than half of patients with advanced forms of disease who took lorlatinib were still alive after five years with no progression

👇🇦🇺"Trial results for new lung cancer drug are ‘off the charts’, say doctors" #Lorlatinib #Melbourne #Australia #LungCancerBreakthrought #ASCO #PeterMacCallumCancerCentre